
    
      Patients with EGFR mutation and presented secondary resistance to prior first-generation
      EGFR-TKI should have received biopsy of at least on progressed lesions and are able to
      provide tissues for pathological examination and NGS testing.All enrolled patients will be
      followed up to clinical outcome (treatments, tumor response, survival, etc).
    
  